This trial is recruiting individuals with acute cervical (neck area) spinal cord injuries to test an oral drug called Riluzole, a medication already approved for amyotrophic lateral sclerosis (ALS). Earlier studies suggest Riluzole is safe, may preserve spinal cord nerve tissue, and may improve behavioral outcomes. The trial will investigate whether the drug improves strength, recovery, and quality of life. Participants will receive the drug or placebo within 24 hours of injury for 14 days. Neither investigator nor participant will know who is in the treatment arm; this “masking” ensures unbiased procedures and objective outcomes.
Traumatic
Type
Details
Within 12 hours of the injury, the participant must be at one of the hospital study centers. The participant will be administered Riluzole or placebo orally twice-a-day for 14 days. Outcome assessments will be performed on day 1, 3, 7, Week 2, Month 3, 6 and 12 post-administration.
Main benefits
General health
Additional benefits
Arm/hand function
Mental health and psychosocial factors
Sensory function
Standing/walking/mobility
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more